Home
GANX
GANX News

Latest Gain Therapeutics Inc. (GANX) News on May 9, 2025

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

GlobeNewswire

8 days ago

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

GlobeNewswire

9 days ago

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

Is Gain Therapeutics (GANX) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?

Insider Monkey

a month ago

Is Gain Therapeutics (GANX) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?

Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update

GlobeNewswire

a month ago

Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update

Gain Therapeutics Announces Poster Presentation at AD/PD 2025

GlobeNewswire

a month ago

Gain Therapeutics Announces Poster Presentation at AD/PD 2025

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

GlobeNewswire

a month ago

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

MT Newswires

2 months ago

Gain Therapeutics Begins Dosing Parkinson's Patients in GT-02287 Study

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease

ACCESS Newswire

2 months ago

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease

GlobeNewswire

2 months ago

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

GlobeNewswire

2 months ago

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

GlobeNewswire

3 months ago

Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

Gain Therapeutics To Participate in Upcoming Investor Conferences

GlobeNewswire

3 months ago

Gain Therapeutics To Participate in Upcoming Investor Conferences

All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy

Zacks

4 months ago

All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy

Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287

GlobeNewswire

4 months ago

Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287

Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

GlobeNewswire

4 months ago

Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

Gain Therapeutics’ GT-02287 study to deliver positive findings, says Roth MKM

TipRanks

4 months ago

Gain Therapeutics’ GT-02287 study to deliver positive findings, says Roth MKM

MT Newswires

5 months ago

Gain Therapeutics Says Australia Approves Start of Phase 1b Parkinson's Disease Study

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease

GlobeNewswire

5 months ago

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease

Gain Therapeutics To Present At Biotech Showcase 2025

GlobeNewswire

5 months ago

Gain Therapeutics To Present At Biotech Showcase 2025

MT Newswires

5 months ago

Roth Initiates Gain Therapeutics at Buy With $7 Price Target

Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

GlobeNewswire

6 months ago

Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2

GlobeNewswire

7 months ago

Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2

Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

GlobeNewswire

7 months ago

Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference

GlobeNewswire

7 months ago

Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

GlobeNewswire

7 months ago

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

Gain Therapeutics to Participate at Upcoming Investor Conferences

GlobeNewswire

7 months ago

Gain Therapeutics to Participate at Upcoming Investor Conferences

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

GlobeNewswire

7 months ago

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease

GlobeNewswire

7 months ago

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024

GlobeNewswire

8 months ago

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024

Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

8 months ago

Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Gain Therapeutics reports positive data from Phase I Parkinson’s treatment trial

Clinical Trials Arena

8 months ago

Gain Therapeutics reports positive data from Phase I Parkinson’s treatment trial

MT Newswires

8 months ago

Gain Therapeutics Says Phase 1 Data Confirm Safety of Parkinson's Disease Drug Candidate

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease

GlobeNewswire

8 months ago

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease

MT Newswires

9 months ago

Oppenheimer Adjusts Gain Therapeutics Price Target to $8 From $9

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

GlobeNewswire

9 months ago

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference

GlobeNewswire

9 months ago

Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease

GlobeNewswire

10 months ago

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease

Gain Therapeutics (GANX) Upgraded to Buy: Here's Why

Zacks

10 months ago

Gain Therapeutics (GANX) Upgraded to Buy: Here's Why

MT Newswires

10 months ago

HC Wainwright Trims Price Target on Gain Therapeutics to $8 From $9, Maintains Buy Rating

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

GlobeNewswire

10 months ago

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

MT Newswires

10 months ago

Gain Therapeutics Names Gene Mack as Interim Chief Executive Officer

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

GlobeNewswire

10 months ago

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease

GlobeNewswire

10 months ago

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

GlobeNewswire

10 months ago

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

MT Newswires

a year ago

Top Midday Decliners

MT Newswires

a year ago

Gain Therapeutics Shares Tumble After Company Prices $11.0 Million Public Offering

MT Newswires

a year ago

Top Premarket Decliners

Gain Therapeutics Announces Pricing of $11.0 Million Public Offering

GlobeNewswire

a year ago

Gain Therapeutics Announces Pricing of $11.0 Million Public Offering

MT Newswires

a year ago

Gain Therapeutics Plans Common Stock Offering to Finance Treatment for Neurodegenerative Disorders; Shares Fall After Hours

Gain Therapeutics Announces Proposed Public Offering

GlobeNewswire

a year ago

Gain Therapeutics Announces Proposed Public Offering

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024

GlobeNewswire

a year ago

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024

Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update

GlobeNewswire

a year ago

Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update

Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know

Zacks

a year ago

Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

GlobeNewswire

a year ago

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher

Zacks

a year ago

Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher

Insiders are Piling into These 10 Healthcare Stocks in 2024

Insider Monkey

a year ago

Insiders are Piling into These 10 Healthcare Stocks in 2024

Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)

Zacks

a year ago

Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)

Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?

Zacks

a year ago

Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

GlobeNewswire

a year ago

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

Director Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX)

GuruFocus.com

a year ago

Director Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX)

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

GlobeNewswire

a year ago

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

GlobeNewswire

a year ago

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

Gain Therapeutics to Present at Public Ventures Discovery Day

GlobeNewswire

a year ago

Gain Therapeutics to Present at Public Ventures Discovery Day

EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease

Benzinga

a year ago

EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease

Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease

GlobeNewswire

a year ago

Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

GlobeNewswire

a year ago

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

GlobeNewswire

a year ago

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

GlobeNewswire

a year ago

UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

GlobeNewswire

a year ago

Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

Natural Health Trends to Report Fourth Quarter 2023 Financial Results on February 7th

GlobeNewswire

a year ago

Natural Health Trends to Report Fourth Quarter 2023 Financial Results on February 7th

Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update

GlobeNewswire

a year ago

Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update

3 Penny Stocks to Turn $999 Into $1 Million: January 2024

InvestorPlace

a year ago

3 Penny Stocks to Turn $999 Into $1 Million: January 2024

Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq

GlobeNewswire

a year ago

Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq

Gain Therapeutics, Inc. (GANX) Upgraded to Strong Buy: Here's What You Should Know

Zacks

a year ago

Gain Therapeutics, Inc. (GANX) Upgraded to Strong Buy: Here's What You Should Know

Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why

Zacks

a year ago

Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why

CCSC Technology International Holdings Limited Announces Closing of Initial Public Offering

GlobeNewswire

a year ago

CCSC Technology International Holdings Limited Announces Closing of Initial Public Offering

Shareholders in Southside Bancshares (NASDAQ:SBSI) are in the red if they invested a year ago

Simply Wall St.

a year ago

Shareholders in Southside Bancshares (NASDAQ:SBSI) are in the red if they invested a year ago

Fidelity D & D Bancorp, Inc. First Quarter 2024 Dividend

GlobeNewswire

a year ago

Fidelity D & D Bancorp, Inc. First Quarter 2024 Dividend

7 A-Rated Software Stocks to Buy in January

InvestorPlace

a year ago

7 A-Rated Software Stocks to Buy in January

Vast Announces Appointment of Two Additional Directors to its Recently Expanded Board of Directors

Business Wire

a year ago

Vast Announces Appointment of Two Additional Directors to its Recently Expanded Board of Directors

Is Lakeland Industries (LAKE) a Solid Growth Stock? 3 Reasons to Think "Yes"

Zacks

a year ago

Is Lakeland Industries (LAKE) a Solid Growth Stock? 3 Reasons to Think "Yes"

Globalink Investment Inc. Announces Extension of the Deadline to Complete a Business Combination to February 9, 2024

GlobeNewswire

a year ago

Globalink Investment Inc. Announces Extension of the Deadline to Complete a Business Combination to February 9, 2024

Fenbo Holdings Limited Announces Appointment of Mr. Meng Derong as Co-Chairman and Independent Non-Executive Director

GlobeNewswire

a year ago

Fenbo Holdings Limited Announces Appointment of Mr. Meng Derong as Co-Chairman and Independent Non-Executive Director

How BankFinancial (BFIN) Stock Stands Out in a Strong Industry

Zacks

a year ago

How BankFinancial (BFIN) Stock Stands Out in a Strong Industry

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024

GlobeNewswire

a year ago

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024

Chimerix Appoints Lisa Decker to Board of Directors

GlobeNewswire

a year ago

Chimerix Appoints Lisa Decker to Board of Directors

Peoples Bancorp of North Carolina, Inc.'s (NASDAQ:PEBK) market cap touched US$167m last week, benefiting both individual investors who own 43% as well as institutions

Simply Wall St.

a year ago

Peoples Bancorp of North Carolina, Inc.'s (NASDAQ:PEBK) market cap touched US$167m last week, benefiting both individual investors who own 43% as well as institutions

Investors in Natural Health Trends (NASDAQ:NHTC) have unfortunately lost 49% over the last five years

Simply Wall St.

a year ago

Investors in Natural Health Trends (NASDAQ:NHTC) have unfortunately lost 49% over the last five years

Taylor Devices (NASDAQ:TAYD) Shareholders Will Want The ROCE Trajectory To Continue

Simply Wall St.

a year ago

Taylor Devices (NASDAQ:TAYD) Shareholders Will Want The ROCE Trajectory To Continue

Bears are Losing Control Over Gain Therapeutics, Inc. (GANX), Here's Why It's a 'Buy' Now

Zacks

a year ago

Bears are Losing Control Over Gain Therapeutics, Inc. (GANX), Here's Why It's a 'Buy' Now

Positive Signs As Multiple Insiders Buy Chimerix Stock

Simply Wall St.

a year ago

Positive Signs As Multiple Insiders Buy Chimerix Stock

Gabelli Global Utility & Income Trust Adds June 26, 2024 as Put Date for Series B Preferred Shares

GlobeNewswire

a year ago

Gabelli Global Utility & Income Trust Adds June 26, 2024 as Put Date for Series B Preferred Shares

Purple Announces Positive Black Friday/Cyber Monday Weekend Selling Period and Reiterates 2023 Full Year Outlook Ahead of Investor Conferences

PR Newswire

a year ago

Purple Announces Positive Black Friday/Cyber Monday Weekend Selling Period and Reiterates 2023 Full Year Outlook Ahead of Investor Conferences

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research

GlobeNewswire

a year ago

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

GlobeNewswire

a year ago

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

Gain Therapeutics to Participate in AI Driven Drug Discovery Summit

GlobeNewswire

a year ago

Gain Therapeutics to Participate in AI Driven Drug Discovery Summit

Smart Share Global Limited (NASDAQ:EM) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

Smart Share Global Limited (NASDAQ:EM) Q3 2023 Earnings Call Transcript

Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option

GlobeNewswire

a year ago

Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option

Gabelli Global Utility & Income Trust Alerts Series B Preferred Shareholders of Upcoming Put Date on December 26, 2023

GlobeNewswire

a year ago

Gabelli Global Utility & Income Trust Alerts Series B Preferred Shareholders of Upcoming Put Date on December 26, 2023

PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors

GlobeNewswire

a year ago

PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors

Share on Social Networks: